The University of Guelph neuroscientist is scoping out the brain regions and genes that change as a consequence of pain that lasts for months or even years.
In a first-of-its-kind study, researchers monitored subsecond changes in levels of the neurotransmitters in the human brain, unlocking new insight into their function.
The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.
Levels of active LRRK2 were high even in Parkinson’s patients without a mutation in LRRK2, suggesting that inhibitors of the protein could treat a wider patient population than expected.